TheStreet upgraded shares of Mylan (NASDAQ:MYL) from a c rating to a b- rating in a research note released on Wednesday.

Several other equities research analysts have also recently issued reports on the stock. Wells Fargo & Co set a $43.00 target price on shares of Mylan and gave the stock a hold rating in a research note on Thursday. Zacks Investment Research raised shares of Mylan from a sell rating to a hold rating in a research note on Tuesday. Goldman Sachs Group lifted their target price on shares of Mylan from $46.00 to $52.00 and gave the stock a buy rating in a research note on Thursday, January 11th. Citigroup reaffirmed a buy rating and set a $58.00 target price (up previously from $48.00) on shares of Mylan in a research note on Thursday, January 4th. Finally, Leerink Swann began coverage on shares of Mylan in a research note on Tuesday, January 2nd. They set a market perform rating and a $44.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus price target of $44.19.

Shares of Mylan (NASDAQ MYL) opened at $46.73 on Wednesday. Mylan has a 1-year low of $29.39 and a 1-year high of $47.25. The company has a quick ratio of 0.95, a current ratio of 1.46 and a debt-to-equity ratio of 1.05. The company has a market cap of $24,950.00, a price-to-earnings ratio of 28.15, a P/E/G ratio of 1.49 and a beta of 1.38.

Mylan (NASDAQ:MYL) last announced its earnings results on Monday, November 6th. The company reported $1.10 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by ($0.10). Mylan had a return on equity of 20.63% and a net margin of 7.28%. The business had revenue of $2.99 billion for the quarter, compared to analyst estimates of $3.09 billion. During the same period last year, the firm earned $1.38 EPS. The company’s revenue for the quarter was down 2.3% compared to the same quarter last year. analysts expect that Mylan will post 4.56 earnings per share for the current year.

In other news, CEO Heather M. Bresch sold 75,000 shares of the business’s stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $45.00, for a total transaction of $3,375,000.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 0.69% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. Wells Fargo & Company MN raised its holdings in Mylan by 24.9% in the 2nd quarter. Wells Fargo & Company MN now owns 584,096 shares of the company’s stock valued at $22,675,000 after buying an additional 116,447 shares during the period. Riverhead Capital Management LLC raised its holdings in Mylan by 4.8% in the 2nd quarter. Riverhead Capital Management LLC now owns 7,196 shares of the company’s stock valued at $279,000 after buying an additional 328 shares during the period. Ameriprise Financial Inc. raised its holdings in Mylan by 4.0% in the 2nd quarter. Ameriprise Financial Inc. now owns 279,428 shares of the company’s stock valued at $10,844,000 after buying an additional 10,861 shares during the period. Thrivent Financial For Lutherans raised its holdings in Mylan by 5.9% in the 2nd quarter. Thrivent Financial For Lutherans now owns 289,840 shares of the company’s stock valued at $11,252,000 after buying an additional 16,120 shares during the period. Finally, Rafferty Asset Management LLC raised its holdings in Mylan by 34.8% in the 2nd quarter. Rafferty Asset Management LLC now owns 51,420 shares of the company’s stock valued at $1,996,000 after buying an additional 13,287 shares during the period. 74.90% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This report was first published by Watch List News and is the property of of Watch List News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/thestreet-upgrades-mylan-myl-to-b/1814740.html.

About Mylan

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Analyst Recommendations for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.